Table 3.
Mean values ± SD of evaluated clinical outcomes measured at baseline and after 2 weeks of crenotherapy in females (W2) and males (M2) with high ROM levels at baseline.
| Group | W2 | M2 | p Value | |
|---|---|---|---|---|
| Pain (VAS-score) | before | 3.1 ± 0.8 | 2.0 ± 1.4 | 0.020 |
| after | 2.1 ± 1.2 | 1.1 ± 1.0 | 0.063 | |
| p value | 0.0004 | 0.011 | ||
| Morning Stiffness (VAS-score) | before | 3.0 ± 1.1 | 1.0 ± 0.8 | 0.0001 |
| after | 1.9 ± 1.4 | 0.5 ± 0.76 | 0.021 | |
| p value | 0.003 | 0.04 | ||
| Itch (VAS-score) | before | 2.2 ± 1.5 | 2.0 ± 1.95 | 0.799 |
| after | 0.1 ± 0.4 | 1.0 ± 1.4 | 0.077 | |
| p value | 0.008 | 0.002 |
Abbreviations. W2, females with increased reactive oxygen metabolites at baseline; M2, males with increased reactive oxygen metabolites at baseline.